Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: J Surg Oncol. 2023 Nov 20;129(3):481–488. doi: 10.1002/jso.27521

Table 2.

Unadjusted perioperative and histopathologic outcomes among patients who received neoadjuvant chemotherapy and chemoradiation followed by surgical resection for gastric cancer.

Unmatched Matched

Chemotherapy, N (%) Chemoradiation, N (%) p-value Chemotherapy, N (%) Chemoradiation, N (%) p-value

Perioperative Outcomes
  30-day Readmission 222 (5.3) 387 (6.9) 0.001 168 (5.7) 206 (7.0) 0.042
  30-day Mortality 78 (1.9) 135 (2.4) 0.06 61 (2.1) 84 (2.9) 0.053
  90-day Mortality 183 (4.3) 321 (5.7) 0.002 142 (4.8) 172 (5.8) 0.082
  Length of Stay, median [IQR] 8 [6-11] 9 [7-13] <0.001 8 [6-11] 9 [7-13] <0.001

Histopathologic Outcomes
  Pathologic Complete Response 304 (7.2) 826 (14.7) <0.001 231 (7.9) 439 (14.9) <0.001
  Negative Margins 3,841 (91.0) 5,264 (95.6) <0.001 2,670 (90.6) 2,832 (96.1) <0.001
  Negative Pathologic Lymph Nodes 1,928 (45.7) 3,320 (59.2) <0.001 1,355 (46.0) 1,759 (59.7) <0.001